Isolate all suspected or confirmed cases immediately. Triage patients with a standardised triage tool and evaluate the severity of disease. Follow local infection prevention and control guidelines.
Have a high index of clinical suspicion in all patients who present with fever and/or acute respiratory illness. People with a history of residence/work/travel in a location with a high risk of transmission or community transmission and contacts of probable and confirmed cases are at higher risk of infection.
Suspect the diagnosis in patients with a new continuous cough, fever, or altered sense of taste or smell. Patients may also present with symptoms including dyspnoea, fatigue, myalgia/arthralgia, sore throat, headache, nasal congestion or rhinorrhoea, sputum production, chest tightness, or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea).
Order a real-time reverse transcription polymerase chain reaction (RT-PCR) to confirm the diagnosis. Upper and lower respiratory specimens are preferred. Serological testing may be useful in some settings. Results should be interpreted in the context of the pretest probability of disease.
Be on high alert for children and adolescents with acute gastrointestinal symptoms and signs of cardiac inflammation. Evidence so far suggests a milder or asymptomatic course of disease in children. However, a rare multisystem inflammatory condition with some features similar to those of Kawasaki disease and toxic shock syndrome has been temporally associated with COVID-19 in children and adolescents.
Order the following laboratory investigations in hospitalised patients: full blood count, comprehensive metabolic panel, arterial blood gas, blood glucose level, coagulation screen, inflammatory markers, cardiac biomarkers, serum creatine kinase, and blood and sputum cultures for other pathogens. Pulse oximetry may reveal low oxygen saturation.
Prioritise a chest x-ray in patients who are seriously ill with suspected pneumonia. Consider a computed tomography scan of the chest if chest x-ray is uncertain or normal. Consult local guidelines.
Report all suspected or confirmed cases to your local health authorities. COVID-19 is a notifiable disease.
Early recognition and rapid diagnosis are essential to prevent transmission and provide supportive care in a timely manner.
Have a high index of clinical suspicion for COVID-19 in all patients who present with fever and/or acute respiratory illness; however, be aware that some patients may not present with signs or symptoms of a febrile respiratory illness.
COVID-19 care pathways should be established at local, regional, and national levels for people with suspected or confirmed COVID-19. Screen patients at the first point of contact within the health system based on case definitions and an assessment of symptoms, and enter suspected or confirmed cases into the pathway. Suspected cases should remain in the pathway until proven negative.
Immediately isolate all suspected and confirmed cases and implement local infection prevention and control procedures. Triage patients with a standardised triage tool and evaluate the patient to assess the severity of disease.
COVID-19 is a notifiable disease.
Take a detailed history to ascertain the level of risk for COVID-19 and assess the possibility of other causes, including a travel history and an assessment of risk factors.
Suspect the diagnosis in:
People residing or working in an area with a high risk of transmission (e.g., closed residential settings, humanitarian setting), people residing in or travelling to an area with community transmission, and people working in a health setting (including within health facilities and households) at any time within the 14 days prior to symptom onset
People who have had contact with a probable or confirmed case. A contact is a person who has experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case:
Face-to-face contact with a probable or confirmed case within 1 metre (3 feet) and for at least 15 minutes
Direct physical contact with a probable or confirmed case
Direct care for a patient with probable or confirmed COVID-19 without using recommended personal protective equipment
Other situations as indicated by local risk assessments.
The Centers for Disease Control and Prevention defines a close contact as someone who has been within 2 metres (6 feet) of an infected person for at least 15 minutes over a 24-hour period, beginning 2 days before symptom onset (or 2 days before testing in asymptomatic patients).
Approximately 15% of patients present with the symptom triad of fever, cough, and dyspnoea, and 90% present with more than one symptom. Some patients may be minimally symptomatic or asymptomatic, while others may present with severe pneumonia or complications such as acute respiratory syndrome, septic shock, acute myocardial infarction, venous thromboembolism, or multi-organ failure.
The most common symptoms are:
Altered sense of taste/smell.
Less common symptoms include:
Myalgia or arthralgia
Signs and symptoms of febrile respiratory illness may not possess the necessary sensitivity for early diagnostic suspicion. A Cochrane review found that at least half of patients had a cough, sore throat, fever, myalgia/arthralgia, fatigue, or headache. The presence of fever, myalgia/arthralgia, fatigue, and headache substantially increased the likelihood of COVID-19 when present. Cough and sore throat were common in people without COVID-19, so these symptoms alone were less helpful for diagnosis. No single symptom or sign included in the review could accurately diagnose COVID-19 and the authors concluded that neither the absence or presence of signs or symptoms are accurate enough to rule in or rule out disease. Non-respiratory symptoms may appear before the onset of fever and lower respiratory tract symptoms.
The clinical presentation has varied slightly across geographical locations. Initial impressions from the US note that the clinical presentation may be broader than that observed in China and Italy, with chest pain, headaches, altered mental status, and gastrointestinal symptoms all observed on initial presentation. Severe hepatic and renal dysfunction that spares the lungs has also been observed. Data from the first hospitalised patients in New York found that while the most common presenting symptoms were fever, cough, dyspnoea, and myalgia, gastrointestinal symptoms appeared to be more common than in China.
80% of adults present with mild to moderate illness
14% of adults present with severe illness
5% of adults present with critical illness
1% of adults present with asymptomatic illness.
The most prevalent symptoms in patients with mild to moderate illness, according to one European study, are headache, loss of smell, nasal congestion, cough, asthenia, myalgia, rhinorrhoea, gustatory dysfunction, and sore throat. Fever was reported less commonly. The mean duration of symptoms was 11.5 days. The presentation varied according to age, with younger patients generally having ear, nose, and throat complaints, and older patients generally having fever, fatigue, and loss of appetite. More common symptoms in patients with severe disease include fever, dyspnoea, and anorexia.
The clinical characteristics in pregnant women are similar to those reported for non-pregnant adults. The most common symptoms in pregnant women are fever and cough. However, pregnant women are less likely to report fever and myalgia compared with non-pregnant women of reproductive age.
It is important to note that symptoms such as fever, dyspnoea, gastrointestinal symptoms, and fatigue may overlap with symptoms due to physiological adaptations of pregnancy or adverse pregnancy events.
Atypical presentations may occur, especially in older patients and patients who are immunocompromised (e.g., falls, delirium/confusion, functional decline, reduced mobility, syncope, persistent hiccups, absence of fever). Older patients and those with comorbidities may present with mild symptoms, but have a high risk of deterioration.
There have been case reports of parotitis (possibly related to intraparotid lymphadenitis), oral vesiculobullous lesions, retinal lesions, and androgenetic alopecia in patients with COVID-19; however, it is unknown whether these findings are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as yet.
The pooled prevalence of co-infection with viruses and atypical bacteria in SARS-CoV-2-positive patients was 11.6% (16.8% in studies that tested 100% of patients for co-pathogens).
Bacterial co-infections have been reported in 7% of hospitalised patients, and 14% of patients in intensive care units. The most common bacteria were Mycoplasma pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and Klebsiella pneumoniae. Co-infections with fungal pathogens and viruses (e.g., respiratory syncytial virus, influenza A) were less commonly reported.
Co-infections are more common in critically ill patients.
Co-infections may be associated with protracted respiratory symptoms, prolonged intensive care stay, morbidity, and mortality if not detected and treated early.
Patients with tuberculosis or influenza and SARS-CoV-2 co-infection have an increased risk of mortality, while the clinical outcomes in patients with HIV or chronic hepatitis and SARS-CoV-2 co-infection are comparable to patients without co-infection.
Signs and symptoms may be similar to other common viral respiratory infections and other childhood illnesses, so a high index of suspicion for COVID-19 is required in children.
33% of children present with mild illness
51% of children present with moderate illness
7% of children present with severe illness
5% of children present with critical illness
20% of children present with asymptomatic illness.
Evidence so far suggests a milder, or asymptomatic, course of disease in about 95% of children, but with possible evidence of radiological lung changes in both categories. Fever and cough are the most common symptoms reported in children. Other less common symptoms include sore throat, nasal congestion, and rhinorrhoea. Fever, cough, and dyspnoea are less common in children compared with adults. Children may present with gastrointestinal symptoms more commonly than adults, particularly newborns and infants, and these may be the only symptom. Febrile seizures have been reported rarely. Among children under 5 years of age, 50% were infants and 43% were asymptomatic. The clinical manifestations in children under 5 years of age appear to be milder compared with those of influenza A infection.
Severe disease has been reported rarely in children. In a cross-sectional study of 48 critically ill infants and children in the US, the clinical course and hospital outcomes were better compared with adults. Similar to adults, 80% of critically ill children had pre-existing comorbidities, most commonly immune suppression/cancer, cardiac disease, obesity, and diabetes. It is worth noting that critical disease has been reported more frequently in children under 1 year of age compared with children older than 1 year of age, and vomiting is more common in this age group. There is increasing concern that a related inflammatory syndrome is emerging in children with severe disease. See the Complications external link opens in a new windowsection for more information.
Respiratory tract symptoms and fever are the most common symptoms in neonates. Although illness is usually mild, severe illness, including cases of late-onset neonatal sepsis and encephalitis, has been reported. Severe illness is slightly more common in neonates compared with older children. Infants may present with irritability, crying, feeding difficulties, silent hypoxia, and neurological symptoms.
Co-infections may be more common in children. Co-infection was documented in 6% of children in US and Italian studies, with the most common pathogens being respiratory syncytial virus, rhinoviruses, Epstein-Barr virus, enteroviruses, influenza A, non-SARS coronaviruses, and Streptococcus pneumoniae.
Perform a physical examination. Avoid use of a stethoscope if possible due to risk of viral contamination. Patients may be febrile (with or without chills/rigors) and have obvious cough and/or difficulty breathing. Auscultation of the chest may reveal inspiratory crackles, rales, and/or bronchial breathing in patients with pneumonia or respiratory distress. Patients with respiratory distress may have tachycardia, tachypnoea, or cyanosis accompanying hypoxia. Bradycardia has been noted in a small cohort of patients with mild to moderate disease.
Pulse oximetry may reveal low oxygen saturation (SpO₂ <90%). Clinicians should be aware that patients with COVID-19 can develop ‘silent hypoxia': their oxygen saturations can drop to low levels and precipitate acute respiratory failure without the presence of obvious symptoms of respiratory distress. Only a small proportion of patients have other organ dysfunction, meaning that after the initial phase of acute deterioration, traditional methods of recognising further deterioration (e.g., National Early Warning Score 2 [NEWS2] scores) may not help predict those patients who go on to develop respiratory failure.
While NEWS2 is still recommended for use in patients with COVID-19, the UK Royal College of Physicians now advises that any increase in oxygen requirements in these patients should trigger an escalation call to a competent clinical decision maker, and prompt an initial increase in observations to at least hourly until a clinical review happens.
Order the following laboratory investigations in all patients with severe illness:
Comprehensive metabolic panel
Blood glucose level
Inflammatory markers (e.g., serum C-reactive protein, erythrocyte sedimentation rate, interleukin-6, lactate dehydrogenase, procalcitonin, amyloid A, and ferritin)
Serum creatine kinase and myoglobin.
The most common laboratory abnormalities are lymphopenia, leukocytosis, leukopenia, thrombocytopenia, hypoalbuminaemia, elevated cardiac biomarkers, elevated inflammatory markers, elevated D-dimer, and abnormal liver and renal function. Laboratory abnormalities – in particular, lymphopenia, leukocyte abnormalities, and other markers of systemic inflammation – are less common in children. Most patients (62%) with asymptomatic disease present with normal laboratory parameters. Of those with laboratory abnormalities, leukopenia, lymphopenia, elevated lactate dehydrogenase, and elevated C-reactive protein were the most common findings.
Collect blood and sputum specimens for culture in patients with severe or critical disease to rule out other causes of lower respiratory tract infection and sepsis, especially patients with an atypical epidemiological history. Specimens should be collected prior to starting empirical antimicrobials if possible.
Radial artery puncture animated demonstration
Molecular testing is required to confirm the diagnosis. Order a nucleic acid amplification test, such as real-time reverse-transcription polymerase chain reaction (RT-PCR), for SARS-CoV-2 in patients with suspected infection whenever possible (see the Criteria external link opens in a new windowsection). Tests should be performed according to guidance issued by local health authorities and adhere to appropriate biosafety practices.
Who to test
Base decisions about who to test on clinical and epidemiological factors.
In the UK, testing is recommended in:
People with symptoms of new continuous cough, high temperature, or altered sense of smell/taste
People with acute respiratory infection, influenza-like illness, clinical or radiological evidence of pneumonia, or acute worsening of underlying respiratory illness, or fever without another cause (whether presenting in primary or secondary care).
In the US, testing is recommended in:
People with symptoms, even if they are mild
People who are asymptomatic and have been in close contact (less than 2 metres [6 feet] for a total of 15 minutes or more over a 24-hour period) with a person with documented infection
People who are asymptomatic and have not been in close contact with a person with documented infection only if required by a healthcare provider or public health official.
The American Academy of Pediatrics recommends testing children with symptoms consistent with COVID-19, children in close contact with an individual with probable or confirmed infection, and children who require screening based on recommendations from public health authorities or other situations (e.g., prior to a medical procedure such as elective surgery or as a school or workplace requirement). The decision to test does not differ by the age of the child. Testing is not recommended for other illnesses that lack shared symptoms (e.g., urinary tract infection, cellulitis), or for children exposed to close contacts of infected individuals unless those contacts are symptomatic or other criteria are met.
Consult local health authorities for guidance as testing priorities depend on local recommendations and available resources.
The optimal specimen for testing depends on the clinical presentation and the time since symptom onset. The World Health Organization (WHO) recommends the following.
Upper respiratory specimens: recommended for early-stage infections, especially asymptomatic or mild cases. Nasopharyngeal swabs yield a more reliable result than oropharyngeal swabs; combined nasopharyngeal and oropharyngeal swabs further improve reliability.
Lower respiratory specimens: recommended for later-stage infections, or patients in whom there is a strong suspicion for infection and their upper respiratory tract specimen test was negative. Suitable specimens are sputum and/or endotracheal aspirate or bronchoalveolar lavage in patients with more severe respiratory disease. However, consider the high risk of aerosol transmission when collecting lower respiratory specimens – an induced sputum specimen is not recommended as it may increase the risk of aerosol transmission.
Other respiratory specimens: studies on combined oropharyngeal and nares/nasal swabs, mid-turbinate or lower nasal or nares swabs, or tongue swabs have been conducted; however, further assessment and validation is required. Oral fluid collection may be suitable in some circumstances (e.g., young children, older patients with dementia).
Saliva: meta-analyses of paired saliva samples and nasopharyngeal swabs found no statistically significant difference in sensitivity or specificity between these specimens for SARS-CoV-2 detection, especially in the ambulatory setting. Sensitivity was not significantly different among asymptomatic people and outpatients. Methods of saliva collection may affect sensitivity. The WHO does not currently recommend the use of saliva as the sole specimen type for routine clinical diagnostics. In contrast, the Infectious Diseases Society of America recommends saliva as a suitable option for molecular testing in symptomatic people.
Faecal specimens: consider when upper or lower respiratory specimens are negative and the clinical suspicion for infection remains (may be used from the second week after symptom onset).
Recommended specimen types may differ between countries. For example, in the US, the Centers for Disease Control and Prevention (CDC) recommends the following upper respiratory specimens: nasopharyngeal or oropharyngeal swab; nasal mid-turbinate swab; anterior nares swab; or nasopharyngeal/nasal wash/aspirate. Recommended lower respiratory tract specimens include: sputum, bronchoalveolar lavage, tracheal aspirate, pleural fluid, and lung biopsy. Nasal mid-turbinate swab is an acceptable specimen for home or onsite self-collection.
Collect specimens under appropriate infection prevention and control procedures.
A positive RT-PCR result confirms SARS-CoV-2 infection. If the result is negative, and there is still a clinical suspicion of infection (e.g., an epidemiological link, typical x-ray findings, absence of another aetiology), resample the patient and repeat the test. A positive result confirms infection. If the second test is negative, consider serological testing (see below).
Genomic sequencing is not routinely recommended, but may be useful to investigate the dynamics of an outbreak, including changes in the size of an epidemic over time, its spatiotemporal spread, and testing hypotheses about transmission routes.
Complications of nasal swab testing
Complications associated with nasal swab testing are not well characterised. Adverse effects may include epistaxis, nasal discomfort, headache, ear discomfort, and rhinorrhoea.
A case of iatrogenic cerebrospinal fluid leak has been reported after nasal testing for COVID-19 in a woman with an undiagnosed skull base defect at the fovea ethmoidalis.
Testing for other infections
Collect nasopharyngeal swabs for testing to rule out infection with other respiratory pathogens (e.g., influenza, atypical pathogens) when clinically indicated according to local guidance. Depending on local epidemiology and clinical symptoms, test for other potential causes including malaria, dengue fever, and typhoid fever as appropriate. It is important to note that co-infections can occur, and a positive test for a non-COVID-19 pathogen does not rule out COVID-19.
When SARS-CoV-2 and influenza viruses are co-circulating, test for both viruses in all hospitalised patients with acute respiratory illness, and only test for influenza virus in outpatients with acute respiratory illness if the results will change clinical management of the patient.
The WHO recommends that healthcare providers consider a positive or negative result in combination with specimen type, clinical observations, patient history, and epidemiological information. It also recommends that laboratories ensure that specimens with high cycle threshold values are not incorrectly assigned a positive result due to background noise, and that they provide the cycle threshold value in the report to the healthcare provider.
Interpret RT-PCR test results with caution.
The evidence for the use of RT-PCR in the diagnosis of COVID-19 is still emerging, and uncertainties about its efficacy and accuracy remain. Estimates of diagnostic accuracy need to be interpreted with caution in the absence of a definitive reference standard to diagnose or rule out COVID-19. Also, more evidence is needed about the efficacy of testing outside of hospital settings and in asymptomatic or mild cases.
Few studies have attempted to culture live SARS-CoV-2 virus from human samples. This is an issue because viral culture is regarded as a gold standard test against which any diagnostic index test for viruses must be measured and calibrated, to understand the predictive properties of that test. Prospective routine testing of reference and viral culture specimens is necessary to establish the usefulness and reliability of RT-PCR to diagnose COVID-19, and its relation to patients factors such as date of onset of symptoms and copy threshold, in order to help predict infectivity.
As there is no clear-cut ‘gold standard’ for COVID-19 testing, evaluating test results can be challenging. Clinical adjudication may be the best available ‘gold standard’ based on repeat swabs, history, clinical presentation, and chest imaging.
It is not clear whether a positive result always indicates the presence of infectious virus.
RT-PCR detects viral RNA, but it is not fully understood how that represents infectious virus. Complete live viruses are necessary for transmission, not the fragments identified by PCR. This could ultimately lead to restrictions for people who do not present an infection risk. Because inactivated RNA degrades slowly over time, it may still be detected many weeks after the patient is no longer infectious.
One study found that only 28.9% of positive RT-PCR SARS-CoV-2 samples demonstrated viral growth when incubated on Vero cells. There was no growth in samples with a RT-PCR cycle threshold >24, or when the symptom onset to test time was >8 days. Therefore, infectivity of patients with a cycle threshold >24 and duration of symptoms >8 days may be low. Another study found that patients with a cycle threshold of 34 or above do not excrete infectious virus. A systematic review found that cycle threshold values were significantly lower and log copies higher in specimens that produce live virus culture. Those with high cycle threshold are unlikely to have infectious potential.
Interpreting test results depends on the accuracy of the test itself, and the pre- and post-test probabilities of disease. The accuracy of the result depends on various factors including the site and quality of sampling, stage of disease, degree of viral multiplication or clearance, and disease prevalence.
Sensitivity and specificity: the pooled sensitivity has been estimated to be 87.8%, with the specificity estimated to be in the range of 87.7% to 100%.
Pretest probability: the pretest probability estimate should be made using knowledge of local rates of infection from national and regional data, as well as the patient’s symptoms, potential exposure to cases, a previous medical history of COVID-19 or the presence of antibodies, and the likelihood of an alternative diagnosis. When the pretest probability is low, positive results should be interpreted with caution, and ideally a second specimen tested for confirmation.
Post-test probability: the lower the prevalence of disease in a given population, the lower the post-test probability. For example, if a test with a specificity of 99% is used to test a high-risk symptomatic population where the likelihood of infection is 50%, the positive predictive value is 99%. This means that for every 100 people with a positive test result, 99 people will have SARS-CoV-2 infection but 1 person without infection will have a false-positive result. Conversely, in a low-risk asymptomatic population where the likelihood of infection is low (e.g., 0.05%), the positive predictive value is around 4.3%. This means that for every 100 people with a positive test result, 4 to 5 people will have SARS-CoV-2 infection, but 95 to 96 people without infection will have a false-positive result.
False-positive results can be caused by a laboratory error or a cross-reaction with antibodies formed by current and past exposure to seasonal human coronavirus infections (e.g., common cold). False-positive results are more likely when the prevalence of SARS-COV-2 is moderate to low.
There is a lack of data on the rate of false-positive tests. However, preliminary estimates in the UK are in the range of 0.8% to 4%. This rate could translate into a significant proportion of daily false-positive results due to the current low prevalence of the virus in the UK population, adversely affecting the positive predictive value of the test.
Examples of the potential consequences of false-positive test results include:
Unnecessarily postponing or cancelling elective procedures or treatments
Potential exposure to infection following a wrong pathway in hospital settings during urgent hospital admissions
Financial losses due to self-isolation, income losses, and cancelled travel
Psychological damage due to misdiagnosis including fear of infecting others or stigmatisation
Increased depression or domestic violence due to lockdown and isolation
Overestimating the incidence and extent of asymptomatic infection in the population.
False-negative rates of between 2% and 29% have been reported. A systematic review found that the false-negative rate varied across studies from 1.8% to 58% (median 11%); however, there was substantial and largely unexplained heterogeneity across studies.
The probability of a false-negative result in an infected person decreases from 100% on day 1 of infection to 67% on day 4. The median false-negative rate drops to 38% on the day of symptom onset, decreases to 20% on day 8, and then starts to increase again from day 9.
Examples of the potential consequences of false-negative test results include:
Patients may be moved into non-COVID-19 wards leading to spread of hospital-acquired infection
Carers could spread infection to vulnerable dependents
Healthcare workers risk spreading the infection to multiple vulnerable individuals.
Serology cannot be used as a standalone diagnostic test for acute SARS-CoV-2 infections. However, it may be useful in various settings (e.g, negative molecular testing, diagnosing patients with late presentation or prolonged symptoms, serosurveillance studies).
The WHO recommends collecting a paired serum sample, one specimen in the acute phase and one in the convalescent phase 2 to 4 weeks later, in patients where infection is strongly suspected and the RT-PCR result is negative.
Seroconversion or a rise in antibody titres in paired sera help to confirm whether the infection is recent and/or acute. If the initial sample tests positive, this could be due to a past infection that is not related to the current illness.
Seroconversion may be faster and more robust in patients with severe disease compared with those with mild disease or asymptomatic infection.
The CDC recommends serological testing as a method to support the diagnosis of acute infection in patients who present late (i.e., 9 to 14 days after symptom onset) in addition to other viral detection methods (e.g., RT-PCR, antigen detection tests), or patients who present with late complications (e.g., paediatric inflammatory multisystem syndrome in children).
Assays with US Food and Drug Administration emergency-use authorisation are preferred. There is no advantage of assays whether they test for immunoglobulin G (IgG), IgM and IgG, or total antibody.
The test’s positive predictive value should be optimised by choosing tests with high specificity (e.g., >99.5%) and testing people or populations with a high pretest probability of having antibodies, or using an orthogonal testing algorithm. Results should be interpreted in the context of the expected predictive values (positive and negative).
The Infectious Diseases Society of America recommends serological testing in the following circumstances:
Evaluation of patients with a high clinical suspicion for infection when molecular diagnostic testing is negative and at least 2 weeks have passed since symptom onset
Evaluation of paediatric inflammatory multisystem syndrome in children
A Cochrane review found that antibody tests for IgG/IgM only detected 30% of people with COVID-19 when the test was performed 1 week after the onset of symptoms, but accuracy increased in week 2 with 70% detected and week 3 with over 90% detected. Data beyond 3 weeks were limited. Tests gave false-positive results in 2% of patients without COVID-19. The review found that the sensitivity of antibody tests is too low in the first week since symptom onset to have a primary role in the diagnosis of COVID-19, but tests are likely to have a useful role in detecting previous infection if used 15 or more days after symptom onset (although there were very little data beyond 35 days).
The evidence for the use of antibody tests in the diagnosis of COVID-19 is still emerging, and uncertainties about their efficacy and accuracy remain. Estimates of diagnostic accuracy need to be interpreted with caution in the absence of a definitive reference standard to diagnose or rule out COVID-19. More evidence is needed about the efficacy of testing outside of hospital settings and in asymptomatic or mild cases. The estimated sensitivity of antibody tests ranged from 18.4% to 96.1% (the lowest reported sensitivity was from a point-of-care test, although a sensitivity <50% was reported for one laboratory test), and specificity ranged from 88.9% to 100%.
Understanding of the antibody response to SARS-CoV-2 is still emerging; therefore, antibody detection tests must be used with caution, and not used to determine acute infections.
Results do not indicate the presence or absence of current or previous infection with certainty as IgM and IgG antibodies may take 1 to 3 weeks to develop after infection. A reliable diagnosis is often only possible in the recovery phase when opportunities for management or interruption of transmission have passed.
The duration of the persistence of antibodies produced in response to SARS-CoV-2 is still under investigation. Some people may not develop detectable antibodies after infection, and in those who do, antibody levels may wane over time to undetectable levels. The presence of antibodies that bind to SARS-CoV-2 does not guarantee that they are neutralising antibodies, or that they offer protective immunity.
Some tests may exhibit cross-reactivity with other coronaviruses, such as those that cause the common cold, which can result in false-positive results.
Tests should not be used to determine the immune status of an individual, or to make decisions about grouping people residing in or being admitted to congregate settings (e.g., schools, dormitories, correctional facilities) or people returning to their workplace.
While rapid antibody detection kits have been approved for the qualitative detection of SARS-CoV-2 IgG/IgM antibodies in serum, plasma, or whole blood, the WHO does not recommend the use of these tests outside of research settings as they have not been validated as yet.
Evidence is particularly weak for point-of-care serological tests. A meta-analysis found that the overall sensitivity of chemiluminescent immunoassays (CLIAs) for IgG or IgM was approximately 98%, and the sensitivity of enzyme-linked immunosorbent assays (ELISAs) was 84%; however, lateral flow immunoassays (LFIAs), which have been developed as point-of-care tests, had the lowest sensitivity at 66%. Test sensitivity was highest 3 or more weeks after onset of symptoms. Available evidence does not support the use of existing point-of-care serological tests.
Antigen testing relies on direct detection of SARS-CoV-2 viral proteins in nasal swabs and other respiratory specimens using a lateral flow immunoassay. Results are usually available in less than 30 minutes. While antigen tests are substantially less sensitive than RT-PCR, they offer the possibility of rapid, inexpensive, and early detection of the most infectious cases in appropriate settings. If used, testing should occur within the first 5 to 7 days following the onset of symptoms.
The WHO recommends antigen testing only in certain scenarios where RT-PCR is unavailable or where prolonged turnaround times preclude clinical utility, provided that the test meets the minimum performance requirements of ≥80% sensitivity and ≥97% specificity compared with a RT-PCR reference assay.
The US Food and Drug Administration has warned that false positive results can occur with antigen tests, including when users do not follow the instructions for use, and that the number of false positive tests increases as disease prevalence decreases.
Laboratory-based (non-rapid) antigen tests are also available in some countries.
All imaging procedures should be performed according to local infection prevention and control procedures to prevent transmission. Chest imaging is considered safe in pregnant women.
Order a chest x-ray in all patients with suspected pneumonia. Unilateral lung infiltrates are found in 25% of patients, and bilateral lung infiltrates are found in 75% of patients. Although chest x-ray appears to have a lower sensitivity compared with chest CT, it has the advantages of being less resource-intensive, associated with lower radiation doses, easier to repeat sequentially, and portable.
Consider ordering a CT scan of the chest. CT imaging is the primary imaging modality in some countries, such as China. It may be helpful in making the diagnosis, guiding individual patient management decisions, aiding the diagnosis of complications, or giving clues to an alternative diagnosis. However, it is not diagnostic for COVID-19 and local guidance should be consulted on whether to perform a CT scan.
The British Society of Thoracic Imaging (BSTI) recommends CT imaging in patients with clinically suspected COVID-19 who are seriously ill if chest x-ray is uncertain or normal. Without the suspicion of COVID-19, the radiology is non-specific and could represent many other disease processes. The BSTI in collaboration with NHS England have produced a radiology decision support tool to help clinicians decide whether or not chest imaging should be ordered.
Some institutions in the UK recommend a more pragmatic approach for patients with high clinical suspicion of COVID-19, with chest CT recommended only after two indeterminate or normal chest x-rays in combination with a negative RT-PCR test.
The American College of Radiology recommends reserving CT for hospitalised, symptomatic patients with specific clinical indications for CT, and emphasises that a normal chest CT does not mean that a patient does not have COVID-19 and that an abnormal chest CT is not specific for COVID-19 diagnosis.
Abnormal chest CT findings have been reported in up to 97% of COVID-19 patients in one meta-analysis of 50,466 hospitalised patients. Evidence of pneumonia on CT may precede a positive RT-PCR result for SARS-CoV-2 in some patients. CT imaging abnormalities may be present in asymptomatic patients. The pooled estimate of the rate of positive chest CT findings in asymptomatic cases was 47.6% (mainly ground-glass opacity). Some patients may present with a normal chest finding despite a positive RT-PCR. Also, results of RT-PCR testing may be false-negative, so patients with typical CT findings should have repeat RT-PCR testing to confirm the diagnosis. CT is more sensitive than RT-PCR in detecting COVID-19, but has a very low specificity.
The most common findings are ground-glass opacity, either in isolation or co-existing with other findings such as consolidation, interlobular septal thickening, or crazy-paving pattern. The most common distribution pattern is bilateral, peripheral/subpleural, posterior distribution of the opacities, with a lower lobe predominance. Extensive/multilobar involvement with consolidations is more common in older patients and those with severe disease.
Ground-glass opacity has the highest diagnostic performance for COVID-19 pneumonia, followed by ground-glass opacity plus consolidation, and consolidation only. The simultaneous presence of ground-glass opacity and other features of viral pneumonia had optimum performance in the detection of COVID-19 (sensitivity 90% and specificity 89%).
CT scan generally shows an increase in the size, number, and density of ground-glass opacities in the early follow-up period, with a progression to mixed areas of ground-glass opacities, consolidations, and crazy paving peaking at day 10 to 11, before gradually resolving or persisting as patchy fibrosis.
A small comparative study found that patients with COVID-19 are more likely to have bilateral involvement with multiple mottling and ground-glass opacity compared with other types of pneumonia.
Children frequently have normal or mild CT chest findings. The most common signs in children are patchy ground-glass opacity and, less frequently, non-specific patchy shadows, areas of consolidation, and a halo sign. Abnormalities are more common in the lower lobes and are predominantly unilateral. Pleural effusion is rare. Children may have signs of pneumonia on chest imaging despite having minimal or no symptoms.
Pulmonary vascular enlargement, interlobular or intralobular septal thickening, adjacent pleural thickening, air bronchograms, subpleural lines, crazy-paving pattern, bronchus distortion, bronchiectasis, vacuolar retraction sign, and halo sign are atypical features. Pleural effusion, pericardial effusion, cavitation, pneumothorax, and mediastinal lymphadenopathy have also been reported rarely.
The WHO recommends chest imaging in the following scenarios:
Symptomatic patients with suspected COVID-19 when RT-PCR is not available, RT-PCR test results are delayed, or initial RT-PCR testing is negative but there is a high clinical suspicion for COVID-19 (for diagnosis)
Patients with suspected or confirmed COVID-19 who are not currently hospitalised and have mild symptoms (to decide on hospital admission versus home discharge)
Patients with suspected or confirmed COVID-19 who are not currently hospitalised and have moderate to severe symptoms (to help decide on regular ward admission versus intensive care unit admission)
Patients with suspected or confirmed COVID-19 who are currently hospitalised and have moderate to severe symptoms (to inform therapeutic management).
Reverse transcription loop-mediated isothermal amplification
Reverse transcription loop-mediated isothermal amplification (RT-LAMP) assays are an emerging test to detect SARS-CoV-2 viral RNA. While assays are simple and quick, there is less evidence for their use. Assays for SARS-CoV-2 have been developed and are being evaluated.
Lung ultrasound is used as a diagnostic tool in some centres as an alternative to chest x-ray and chest CT. Although there is only very low-certainty evidence supporting its diagnostic accuracy, it might be helpful as a supplemental or alternate imaging modality. It has the advantages of portability, bedside evaluation, reduced healthcare worker exposure, easier sterilisation process, absence of ionising radiation exposure, and repeatability during follow-up. It may also be more readily available in resource-limited settings. However, it also has some limitations (e.g., it is unable to discern chronicity of a lesion) and other imaging modalities may be required. B-lines are the prominent pattern in patients with COVID-19, occurring with a pooled frequency of 97%. Pleural line abnormalities are also common, with a pooled frequency of 70%. While these findings are not specific for COVID-19, they increase the likelihood of disease in the context of a characteristic clinical presentation. Other findings include consolidations, pleural thickening, and pleural effusion. May be used in pregnant women and children.
Viral isolation is not recommended as a routine diagnostic procedure. All procedures involving viral isolation in cell culture require trained staff and biosafety level 3 (BSL-3) facilities.
Best Practice has published a separate topic on the management of co-existing conditions in the context of COVID-19. BMJ Best Practice: management of co-existing conditions in the context of COVID-19 external link opens in a new window
Use of this content is subject to our disclaimer